



USPTO Patent Application 09/944,654

564

(1) fm 1623

Content

USPTO Filing Receipt

Reply to Interview Summary

RCE Transmittal Form

Visa Card Payment Form

Request for Continuous Examination
Including claims 6 pages

Response to Office Action dated 07/11/2006
(Final Rejection) 6 pages

Fax No. 571 273 8300

original copy mailed 19 June 08

time & Date Faxed: 05/22 23:50

Faxed From: Doha - Qatar

Fax: 00974 4823 171

Signed

N. Nasser



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
WWW.USPTO.GOV

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/944,564	09/04/2001	1623	1259			24	15

CONFIRMATION NO. 8476

UPDATED FILING RECEIPT



OC000000007223633

AL-JASSIM, Rawaa
2578 River Woods Drive
Naperville, IL 60565

Date Mailed: 12/21/2001

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Nida Abdul-Ghani Nassief, Doha, IRAQ;

Domestic Priority data as claimed by applicant

Foreign Applications

UNITED KINGDOM 9904777.1 03/02/1999

If Required, Foreign Filing License Granted 10/06/2001

Projected Publication Date: 03/28/2002

Non-Publication Request: No

Early Publication Request: No

** SMALL ENTITY **

Title

Asthma/allergy therapy that targets T-lymphocytes and/or eosinophils

Preliminary Class

514

Fax
571 273 8300

(5)

Application No. 09/944,564 Examiner Dr Patrick Lewis Art Unit 1623

Reply to the Interview Summary dated 22 April 2008

Dear Examiner,

Please find following the reply to the interview summary.

Substance of interview including description of the general nature of what was agreed to if an agreement was reached:

1. No Agreement was reached because the claims in the application are not in the proper format for appeal

2. The Examiner Doctor Patrick LEWIS directed me to contact the HSLIE for further assistance regarding the claims.

HSLIE has been contacted: Department of Organic Chemistry Art Unit 1623 Shaojia (Anna) A Jiang, tel # 571-272-0627 and she advises on filing a Request for Continued Examination (RCE)

Following please find the RCE application

3. Ms Shaojia raised the point of a delay in issuing the Office Action. The same point has been raised during discussion with Dr Patrick and he believes that this due to administrative fault and he has contacted the administrative office to clarify this point.

Points raised in the telephone conversation:

Dr Nedaa Nassief asked the examiner about her patent application claims and the examiner decision about allowing the claims.

Dr Lewis believes that the claims did not appear to be in the proper format for appeal and Dr Lewis also added that the use claim are not patentable in the USPTO.

Dr Nedaa inquires about how an Investigational New Drug Application (INDA) as defined by the FDA is protected in the USPTO.

Dr Patrick replies that there is no direct linking between the FDA and USPTO.

Dr Nedaa inquires about how Viagra® was patented, because it is an existing chemical compound for a new application.

Dr Patrick replied that Viagra is protected as a method of treatment.

Here we arrive to a useful point in the discussion because my patent application already contains a method of treatment that has been claimed before in my application.

Accordingly I submit the RCA claiming a method of treatment.

Sincerely,



Dr Nida Nassief